FI112777B - Valmistusmenetelmä antivirus-aktiiviselle farmaseuttiselle öljy-vedessä emulsiolle, jossa on 9-[(2-hydroksietoksi)-metyyli]-guaniini (asyklovir) tai sen suola tai esteri - Google Patents
Valmistusmenetelmä antivirus-aktiiviselle farmaseuttiselle öljy-vedessä emulsiolle, jossa on 9-[(2-hydroksietoksi)-metyyli]-guaniini (asyklovir) tai sen suola tai esteri Download PDFInfo
- Publication number
- FI112777B FI112777B FI951086A FI951086A FI112777B FI 112777 B FI112777 B FI 112777B FI 951086 A FI951086 A FI 951086A FI 951086 A FI951086 A FI 951086A FI 112777 B FI112777 B FI 112777B
- Authority
- FI
- Finland
- Prior art keywords
- acyclovir
- water
- skin
- ester
- salt
- Prior art date
Links
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 150000002148 esters Chemical class 0.000 title claims abstract description 16
- 150000003839 salts Chemical class 0.000 title claims abstract description 16
- 239000007764 o/w emulsion Substances 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims 8
- 230000002155 anti-virotic effect Effects 0.000 title claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 76
- 229960004150 aciclovir Drugs 0.000 claims abstract description 68
- 229940074076 glycerol formal Drugs 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 14
- 238000009472 formulation Methods 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005662 Paraffin oil Substances 0.000 claims abstract description 3
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims abstract description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims abstract description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000008117 stearic acid Substances 0.000 claims abstract description 3
- 239000003871 white petrolatum Substances 0.000 claims abstract description 3
- 229940057995 liquid paraffin Drugs 0.000 claims abstract 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 abstract description 22
- 239000000839 emulsion Substances 0.000 abstract description 17
- 239000012071 phase Substances 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 239000008346 aqueous phase Substances 0.000 abstract description 6
- 239000000470 constituent Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 description 47
- 210000003491 skin Anatomy 0.000 description 42
- 238000012360 testing method Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 230000035515 penetration Effects 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229940107931 zovirax Drugs 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK111392A DK169121B1 (da) | 1992-09-09 | 1992-09-09 | Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf |
| DK111392 | 1992-09-09 | ||
| DK9300288 | 1993-09-09 | ||
| PCT/DK1993/000288 WO1994005258A1 (en) | 1992-09-09 | 1993-09-09 | An antivirally active pharmaceutical oil-in-water emulsion containing 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) or a salt or ester thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI951086A7 FI951086A7 (fi) | 1995-03-08 |
| FI951086A0 FI951086A0 (fi) | 1995-03-08 |
| FI112777B true FI112777B (fi) | 2004-01-15 |
Family
ID=8101156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI951086A FI112777B (fi) | 1992-09-09 | 1995-03-08 | Valmistusmenetelmä antivirus-aktiiviselle farmaseuttiselle öljy-vedessä emulsiolle, jossa on 9-[(2-hydroksietoksi)-metyyli]-guaniini (asyklovir) tai sen suola tai esteri |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0662819B1 (cs) |
| JP (1) | JPH08501089A (cs) |
| AT (1) | ATE137113T1 (cs) |
| AU (1) | AU4945393A (cs) |
| BG (1) | BG62032B1 (cs) |
| BR (1) | BR9307024A (cs) |
| CA (1) | CA2142493A1 (cs) |
| CZ (1) | CZ284007B6 (cs) |
| DE (1) | DE69302396T2 (cs) |
| DK (1) | DK169121B1 (cs) |
| EE (1) | EE03088B1 (cs) |
| ES (1) | ES2086235T3 (cs) |
| FI (1) | FI112777B (cs) |
| GR (1) | GR3019984T3 (cs) |
| HR (1) | HRP931160B1 (cs) |
| HU (1) | HUT72606A (cs) |
| LT (1) | LT3056B (cs) |
| LV (1) | LV10912B (cs) |
| NO (1) | NO308234B1 (cs) |
| PL (1) | PL172663B1 (cs) |
| RO (1) | RO113306B1 (cs) |
| RU (1) | RU2128503C1 (cs) |
| SI (1) | SI9300469A (cs) |
| SK (1) | SK280119B6 (cs) |
| UA (1) | UA41897C2 (cs) |
| WO (1) | WO1994005258A1 (cs) |
| ZA (1) | ZA936661B (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4416674C2 (de) * | 1994-05-11 | 1997-01-30 | Rentschler Arzneimittel | Topische Zubereitung enthaltend Aciclovir |
| ZA96525B (en) * | 1995-02-06 | 1996-08-06 | Astra Ab | Novel pharmaceutical compositions |
| US6440980B1 (en) | 1996-09-17 | 2002-08-27 | Avanir Pharmaceuticals | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| FR2753626B1 (fr) * | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant |
| AU2004202929B2 (en) * | 1999-09-22 | 2006-11-23 | B. Ron Johnson | Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| WO2005067941A1 (es) * | 2004-01-08 | 2005-07-28 | Universidad De Concepcion | Formulacion topica de aciclovir |
| WO2005102307A2 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| US20050257718A1 (en) * | 2004-05-22 | 2005-11-24 | Engelhard Corporation | Natural Pearl in Butylene Glycol |
| WO2007121318A2 (en) * | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| WO2008006085A2 (en) * | 2006-07-07 | 2008-01-10 | University Of Washington | Compositions and methods for predicting inhibitors of protein targets |
| US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| ES2607476T3 (es) | 2009-06-24 | 2017-03-31 | Strategic Science & Technologies, Llc | Composición tópica que contiene ibuprofeno |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| FR3023718B1 (fr) * | 2014-07-16 | 2018-10-12 | Pierre Fabre Medicament | Compositions pharmaceutique et/ou cosmetique decontaminees par haute pression |
| GB201819418D0 (en) | 2018-11-29 | 2019-01-16 | Daniel Calladine Ltd | Anti-viral compositions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523865A (en) | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| GB2080106B (en) * | 1980-07-18 | 1984-03-07 | Weelcome Foundation Ltd | Acyclovin preparations |
-
1992
- 1992-09-09 DK DK111392A patent/DK169121B1/da not_active IP Right Cessation
-
1993
- 1993-09-07 HR HR1113/92A patent/HRP931160B1/xx not_active IP Right Cessation
- 1993-09-09 SK SK291-95A patent/SK280119B6/sk unknown
- 1993-09-09 UA UA95038210A patent/UA41897C2/uk unknown
- 1993-09-09 ES ES93919042T patent/ES2086235T3/es not_active Expired - Lifetime
- 1993-09-09 HU HU9500702A patent/HUT72606A/hu unknown
- 1993-09-09 BR BR9307024A patent/BR9307024A/pt not_active Application Discontinuation
- 1993-09-09 EP EP93919042A patent/EP0662819B1/en not_active Expired - Lifetime
- 1993-09-09 DE DE69302396T patent/DE69302396T2/de not_active Expired - Fee Related
- 1993-09-09 PL PL93307860A patent/PL172663B1/pl unknown
- 1993-09-09 RU RU95110930A patent/RU2128503C1/ru active
- 1993-09-09 SI SI9300469A patent/SI9300469A/sl unknown
- 1993-09-09 CA CA002142493A patent/CA2142493A1/en not_active Abandoned
- 1993-09-09 CZ CZ95599A patent/CZ284007B6/cs unknown
- 1993-09-09 AU AU49453/93A patent/AU4945393A/en not_active Abandoned
- 1993-09-09 AT AT93919042T patent/ATE137113T1/de not_active IP Right Cessation
- 1993-09-09 JP JP6506765A patent/JPH08501089A/ja active Pending
- 1993-09-09 LT LTIP959A patent/LT3056B/lt not_active IP Right Cessation
- 1993-09-09 ZA ZA936661A patent/ZA936661B/xx unknown
- 1993-09-09 RO RO95-00478A patent/RO113306B1/ro unknown
- 1993-09-09 WO PCT/DK1993/000288 patent/WO1994005258A1/en active IP Right Grant
-
1994
- 1994-08-09 EE EE9400083A patent/EE03088B1/xx unknown
-
1995
- 1995-03-08 NO NO950895A patent/NO308234B1/no not_active IP Right Cessation
- 1995-03-08 BG BG99484A patent/BG62032B1/bg unknown
- 1995-03-08 FI FI951086A patent/FI112777B/fi active
- 1995-04-07 LV LVP-95-90A patent/LV10912B/en unknown
-
1996
- 1996-05-20 GR GR960401359T patent/GR3019984T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112777B (fi) | Valmistusmenetelmä antivirus-aktiiviselle farmaseuttiselle öljy-vedessä emulsiolle, jossa on 9-[(2-hydroksietoksi)-metyyli]-guaniini (asyklovir) tai sen suola tai esteri | |
| CA1192496A (en) | Topical pharmaceutical compositions | |
| EP1073470B1 (en) | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients | |
| CA2152907C (en) | Antiviral topical pharmaceutical compositions | |
| KR100867246B1 (ko) | 모발 성장 촉진용 제제 | |
| CA2170016C (en) | Improved method for treating hair loss | |
| JPS6036423A (ja) | Ｎ−（２−ヒドロキシエチル）ピロリドンを含有する浸透局所製薬組成物 | |
| JP2007508261A (ja) | 皮膚残留物を最小化するための経皮的医薬製剤 | |
| AU1313299A (en) | Penetration enhancing and irritation reducing systems | |
| KR20100047840A (ko) | 디클로페낙의 신규한 비수용성 국소 용액 및 이를 제조하는 과정 | |
| KR20070008690A (ko) | 항콜린제를 위한 침투 강화 조성물 | |
| US8771712B2 (en) | Topical administration of acyclovir | |
| US11628177B2 (en) | Compositions and methods for deep dermal drug delivery | |
| JPH07291856A (ja) | 皮膚疾患治療乳剤 | |
| EP0651993B1 (en) | Percutaneously administrable base composition and drug composition prepared therefrom | |
| EP0535237A1 (en) | Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same | |
| Aungst et al. | Transdermal oxymorphone formulation development and methods for evaluating flux and lag times for two skin permeation‐enhancing vehicles | |
| US5128135A (en) | Percutaneous or trans-mucosal absorption enhancers, preparations containing the enhancers, and a method of preparing thereof | |
| JP2881836B2 (ja) | 抗真菌剤 | |
| WO1991015210A1 (en) | Compositions comprising cytotoxic agent and permeation enhancers | |
| EP4545062A1 (en) | TRANSDERMAL MICROEMULSION COMPOSITION COMPRISING LOW MOLECULAR WEIGHT COLLAGEN | |
| ITMI972889A1 (it) | Composizioni farmaceutiche per uso topico e/o transdermale |